ITM Isotope Technologies Munich SE partners with Debiopharm for exclusive global license to develop targeted radiopharmaceuticals for cancer treatment.

ITM Isotope Technologies Munich SE has secured an exclusive global license from Debiopharm for developing peptide-based radiopharmaceuticals targeting CA IX in solid tumors. This partnership aims to advance innovative treatments for cancer, enhancing the potential for targeted therapy in oncology.

September 12, 2024
5 Articles

Further Reading